Pharma BD Deal Intelligence
Roche's $1.5B tender offer for Poseida Therapeutics handed the Swiss giant an allogeneic CAR-T platform at a ~215% premium, anchored by BCMA-targeted P-BCMA-ALLO1 in relapsed/refractory multiple myeloma. The bet: off-the-shelf cell therapy can out-scale autologous CAR-Ts, though the CVR structure ties full value to future clinical hurdles.
Roche acquired Poseida Therapeutics for $1.0B for cell therapy for cancer.
Poseida Therapeutics announces agreement to be acquired by Roche Holdings: $9.00/share cash plus CVR up to $4.00/share.
Major pharmaceutical company Roche buys cell and gene developer Poseida Therapeutics in $1.5 billion acquisition deal
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Roche (via subsidiary Blue Giant Acquisition Corp.) acquired San Diego-based cell-therapy developer Poseida Therapeutics in a tender-offer takeover announced 26 November 2024 and completed 8 January 2025. Holders received US$9.00 per share in cash at closing -- a total upfront equity value of approximately US$1.0 billion, a ~215% premium to Poseida's 25 November 2024 close -- plus a non-tradeable contingent value right (CVR) for up to an additional US$4.00 per share, bringing total potential deal value to approximately US$1.5 billion. The acquisition gives Roche Poseida's allogeneic (off-the-shelf) CAR-T platform and lead candidates P-BCMA-ALLO1 (BCMA-targeted, RMAT-designated in relapsed/refractory multiple myeloma), the dual-targeting P-CD19CD20-ALLO1 (B-cell malignancies and autoimmune indications including MS and SLE), and the solid-tumor program P-MUC1C-ALLO1, deepening Roche's bet that allogeneic CAR-Ts can broaden access relative to autologous cell therapies. Poseida was delisted from Nasdaq on close.
35K US cases/yr · $25.0B Global Myeloma Market (2025E)
Multiple myeloma is a plasma-cell malignancy with ~36,000 new US cases and ~12,000 deaths annually, characterized by clonal plasma-cell proliferation in the bone marrow, monoclonal protein, CRAB features (hypercalcemia, renal dysfunction, anemia, bone lesions), and near-universal relapse. BCMA-directed therapy (antibodies, ADCs, bispecifics, autologous CAR-T) has transformed relapsed/refractory disease. Separately, CD19/CD20-directed cell therapies are being investigated in severe B-cell-mediated autoimmune disease (lupus, MS, myositis) to achieve deep B-cell depletion and potential drug-free remission.
Autologous CAR-Ts (Carvykti, Abecma) dominate but have access/cost barriers. Allogeneic approach competes with Allogene, CRISPR Therapeutics.
P-CD19CD20-ALLO1 is an allogeneic dual-targeting CD19+CD20 CAR-T for B-cell malignancies, positioned against a first wave of approved autologous single-target CAR-Ts. Autologous CD19 CAR-T (dominant class): axicabtagene ciloleucel (Yescarta, Gilead/Kite, 2023 sales ~$1.5B), tisagenlecleucel (Kymriah, Novartis), and lisocabtagene maraleucel (Breyanzi, BMS) are FDA-approved for 2L+ R/R LBCL and other B-NHL indications; brexucabtagene autoleucel (Tecartus, Gilead/Kite) is approved for MCL and B-ALL. Autologous dual-target CD19/CD22 CAR-T: Zuma-22/other Gilead programs and investigator-led Stanford/UPenn constructs are in Phase 1/2; no approvals yet. Allogeneic CAR-T (direct MOA competitor — the ~$1B Roche-Poseida thesis): ALLO-501/501A (Allogene, anti-CD19) is in Phase 2 ALPHA-2/EXPAND for R/R LBCL; CTX110/CTX112 (CRISPR Therapeutics, anti-CD19) is in Phase 1/2; cemacabtagene ansegedleucel (formerly CB-010, Caribou Biosciences, anti-CD19) is in Phase 1 ANTLER. Bispecific T-cell engagers (convergent therapeutic pressure): glofitamab (Columvi, Roche — Roche's own product) and epcoritamab (Epkinly, AbbVie/Genmab) are FDA-approved for R/R DLBCL and applying pricing/access pressure on CAR-T with off-the-shelf dosing. Antibody-drug conjugates: loncastuximab tesirine (Zynlonta, ADC Therapeutics) and polatuzumab vedotin (Polivy, Roche). The Poseida thesis is dual-antigen escape prevention plus allogeneic availability; commercial success hinges on durable response versus autologous gold standard.
Roche completed $1.0B acquisition of Poseida Therapeutics, gaining allogeneic CAR-T platform with non-viral piggyBac gene delivery technology.
Non-viral CAR-T platform could address manufacturing challenges. Early pipeline with off-the-shelf potential. $1B measured bet on next-gen cell therapy.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Poseida Therapeutics (this deal) | 2024 | $1.5B | 60 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2024 deals · Roche Holding AG deals · Immunology deals